This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Vanderbilt University. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Daniel C Liebler: Innovator in Cancer Diagnostics
Introduction
Daniel C Liebler is a prominent inventor based in Brentwood, TN (US). He has made significant contributions to the field of cancer diagnostics through his innovative research and patented technologies. With a total of 2 patents, Liebler's work focuses on advancing the understanding and treatment of cancer.
Latest Patents
Liebler's latest patents include groundbreaking methods for analyzing immune checkpoint proteins involved in cancer. One of his patents, titled "Immune checkpoint molecular fitness profiling by mass spectrometry," provides material and methods for determining abundance ratios of various immune checkpoint proteins, such as PD-1, PD-L1, and PD-L2, present in a biospecimen sample. This method utilizes mass spectrometry analysis to quantify peak areas, offering an alternative platform for diagnosing and treating cancer, particularly in cases where antibody recognition is ineffective. Another significant patent is "Protein quantitation in multicellular tissue specimens," which outlines methods for measuring the amount of a target protein in heterogeneous multicellular biospecimens containing multiple cell types.
Career Highlights
Daniel C Liebler is affiliated with Vanderbilt University, where he conducts his research and develops innovative solutions for cancer diagnostics. His work has garnered attention for its potential to improve patient outcomes through more accurate and effective diagnostic methods.
Collaborations
Liebler collaborates with esteemed colleagues, including Lisa J Zimmerman and Hyoungjoo Lee, to further enhance the impact of his research in the field of cancer diagnostics.
Conclusion
Daniel C Liebler's contributions to cancer diagnostics through his patented innovations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer treatment and diagnosis.